OF THE
TIMES
On February 27, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On April 23, 2021, the FDA amended the EUA to include information about a very rare and serious type of blood clot in people who receive the vaccine. The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older.See what the Healthcare Providers administering the vaccine are aware of before administering the jab:
The Department of Health and Human Services correspondence in updates to the EUA Fact Sheet for Healthcare Providers Administering VaccineSee also:
The European Medicines Agency (EMA) has listed Guillain-Barré syndrome (GBI think I know what the warning sign will look like. They've had it for years already!*S) as a very rare side effect of the Janssen Covid vaccine after examining 108 cases and one death worldwide from among recipients of the jab.
R.C.